Eintrag weiter verarbeiten
Immunotherapeutic potential of oncolytic H-1 parvovirus: hints of glioblastoma microenvironment conversion towards immunogenicity
Gespeichert in:
| Veröffentlicht in: | Viruses 9(2017,12), Artikel-Nummer 382, 12 Seiten |
|---|---|
| Personen und Körperschaften: | , , |
| Titel: | Immunotherapeutic potential of oncolytic H-1 parvovirus: hints of glioblastoma microenvironment conversion towards immunogenicity/ Assia L. Angelova, Milena Barf, Karsten Geletneky, Andreas Unterberg and Jean Rommelaere |
| Format: | E-Book-Kapitel |
| Sprache: | Englisch |
| veröffentlicht: |
15 December 2017
|
| Gesamtaufnahme: |
: Viruses, 9(2017,12), Artikel-Nummer 382, 12 Seiten
, volume:9 |
| Schlagwörter: | |
| Quelle: | Verbunddaten SWB Lizenzfreie Online-Ressourcen |
| LEADER | 03996caa a2200613 4500 | ||
|---|---|---|---|
| 001 | 0-1576368491 | ||
| 003 | DE-627 | ||
| 005 | 20220814163435.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180614s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/v9120382 |2 doi | |
| 035 | |a (DE-627)1576368491 | ||
| 035 | |a (DE-576)506368491 | ||
| 035 | |a (DE-599)BSZ506368491 | ||
| 035 | |a (OCoLC)1341011718 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Angelova, Assia L. |e VerfasserIn |0 (DE-588)1079566295 |0 (DE-627)841239908 |0 (DE-576)452802687 |4 aut | |
| 245 | 1 | 0 | |a Immunotherapeutic potential of oncolytic H-1 parvovirus |b hints of glioblastoma microenvironment conversion towards immunogenicity |c Assia L. Angelova, Milena Barf, Karsten Geletneky, Andreas Unterberg and Jean Rommelaere |
| 264 | 1 | |c 15 December 2017 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.06.2018 | ||
| 520 | |a Glioblastoma, one of the most aggressive primary brain tumors, is characterized by highly immunosuppressive microenvironment. This contributes to glioblastoma resistance to standard treatment modalities and allows tumor growth and recurrence. Several immune-targeted approaches have been recently developed and are currently under preclinical and clinical investigation. Oncolytic viruses, including the autonomous protoparvovirus H-1 (H-1PV), show great promise as novel immunotherapeutic tools. In a first phase I/IIa clinical trial (ParvOryx01), H-1PV was safe and well tolerated when locally or systemically administered to recurrent glioblastoma patients. The virus was able to cross the blood-brain (tumor) barrier after intravenous infusion. Importantly, H-1PV treatment of glioblastoma patients was associated with immunogenic changes in the tumor microenvironment. Tumor infiltration with activated cytotoxic T cells, induction of cathepsin B and inducible nitric oxide (NO) synthase (iNOS) expression in tumor-associated microglia/macrophages (TAM), and accumulation of activated TAM in cluster of differentiation (CD) 40 ligand (CD40L)-positive glioblastoma regions was detected. These are the first-in-human observations of H-1PV capacity to switch the immunosuppressed tumor microenvironment towards immunogenicity. Based on this pilot study, we present a tentative model of H-1PV-mediated modulation of glioblastoma microenvironment and propose a combinatorial therapeutic approach taking advantage of H-1PV-induced microglia/macrophage activation for further (pre)clinical testing. | ||
| 650 | 4 | |a immune suppression | |
| 650 | 4 | |a immunogenic conversion | |
| 650 | 4 | |a oncolytic H-1 parvovirus | |
| 650 | 4 | |a oncolytic immunotherapy | |
| 650 | 4 | |a oncolytic virotherapy | |
| 650 | 4 | |a recurrent glioblastoma | |
| 650 | 4 | |a tumor microenvironment | |
| 700 | 1 | |a Geletneky, Karsten |d 1964- |e VerfasserIn |0 (DE-588)123632862 |0 (DE-627)706375475 |0 (DE-576)293799326 |4 aut | |
| 700 | 1 | |a Unterberg, Andreas |e VerfasserIn |0 (DE-588)1032681187 |0 (DE-627)738641200 |0 (DE-576)168441233 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Viruses |d Basel : MDPI, 2009 |g 9(2017,12), Artikel-Nummer 382, 12 Seiten |h Online-Ressource |w (DE-627)609775871 |w (DE-600)2516098-9 |w (DE-576)311326080 |x 1999-4915 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2017 |g number:12 |g extent:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/v9120382 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 936 | u | w | |d 9 |j 2017 |e 12 |g 12 |y 9(2017,12), Artikel-Nummer 382, 12 Seiten |
| 951 | |a AR | ||
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/v9120382 |9 LFER |
| 852 | |a LFER |z 2018-07-10T00:00:00Z | ||
| 970 | |c OD | ||
| 971 | |c EBOOK | ||
| 972 | |c EBOOK | ||
| 973 | |c Aufsatz | ||
| 935 | |a lfer | ||
| 900 | |a Angelova, Assia | ||
| 900 | |a Angelova, A. L. | ||
| 900 | |a Unterberg, Andreas W. | ||
| 900 | |a Unterberg, A. W. | ||
| 900 | |a Unterberg, A. | ||
| 951 | |b XA-DE | ||
| 980 | |a 1576368491 |b 0 |k 1576368491 |o 506368491 |c lfer | ||
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Immunotherapeutic+potential+of+oncolytic+H-1+parvovirus%3A+hints+of+glioblastoma+microenvironment+conversion+towards+immunogenicity&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rft.creator=Angelova%2C+Assia+L.&rft.pub=&rft.format=Journal&rft.language=English&rft.issn=1999-4915 |
|---|
| _version_ | 1757949661068394496 |
|---|---|
| access_facet | Electronic Resources |
| author | Angelova, Assia L., Geletneky, Karsten, Unterberg, Andreas |
| author_facet | Angelova, Assia L., Geletneky, Karsten, Unterberg, Andreas |
| author_role | aut, aut, aut |
| author_sort | Angelova, Assia L. |
| author_variant | a l a al ala, k g kg, a u au |
| callnumber-sort | |
| collection | lfer |
| container_reference | 9(2017,12), Artikel-Nummer 382, 12 Seiten |
| container_title | Viruses |
| contents | Glioblastoma, one of the most aggressive primary brain tumors, is characterized by highly immunosuppressive microenvironment. This contributes to glioblastoma resistance to standard treatment modalities and allows tumor growth and recurrence. Several immune-targeted approaches have been recently developed and are currently under preclinical and clinical investigation. Oncolytic viruses, including the autonomous protoparvovirus H-1 (H-1PV), show great promise as novel immunotherapeutic tools. In a first phase I/IIa clinical trial (ParvOryx01), H-1PV was safe and well tolerated when locally or systemically administered to recurrent glioblastoma patients. The virus was able to cross the blood-brain (tumor) barrier after intravenous infusion. Importantly, H-1PV treatment of glioblastoma patients was associated with immunogenic changes in the tumor microenvironment. Tumor infiltration with activated cytotoxic T cells, induction of cathepsin B and inducible nitric oxide (NO) synthase (iNOS) expression in tumor-associated microglia/macrophages (TAM), and accumulation of activated TAM in cluster of differentiation (CD) 40 ligand (CD40L)-positive glioblastoma regions was detected. These are the first-in-human observations of H-1PV capacity to switch the immunosuppressed tumor microenvironment towards immunogenicity. Based on this pilot study, we present a tentative model of H-1PV-mediated modulation of glioblastoma microenvironment and propose a combinatorial therapeutic approach taking advantage of H-1PV-induced microglia/macrophage activation for further (pre)clinical testing. |
| ctrlnum | (DE-627)1576368491, (DE-576)506368491, (DE-599)BSZ506368491, (OCoLC)1341011718 |
| doi_str_mv | 10.3390/v9120382 |
| facet_avail | Online, Free |
| finc_class_facet | not assigned |
| finc_id_str | 0021171043 |
| footnote | Gesehen am 14.06.2018 |
| format | ElectronicBookComponentPart |
| format_access_txtF_mv | Article, E-Article |
| format_de105 | Ebook |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_del152 | Buch |
| format_detail_txtF_mv | text-online-monograph-child |
| format_dezi4 | e-Book |
| format_finc | Article, E-Article |
| format_legacy | ElectronicBookPart |
| format_strict_txtF_mv | E-Article |
| geogr_code | not assigned |
| geogr_code_person | Germany |
| hierarchy_parent_id | 0-609775871 |
| hierarchy_parent_title | Viruses |
| hierarchy_sequence | 9(2017,12), Artikel-Nummer 382, 12 Seiten |
| hierarchy_top_id | 0-609775871 |
| hierarchy_top_title | Viruses |
| id | 0-1576368491 |
| illustrated | Not Illustrated |
| imprint | 15 December 2017 |
| imprint_str_mv | 15 December 2017 |
| institution | DE-D117, DE-105, LFER, DE-Ch1, DE-15, DE-14, DE-Zwi2 |
| is_hierarchy_id | 0-1576368491 |
| is_hierarchy_title | Immunotherapeutic potential of oncolytic H-1 parvovirus: hints of glioblastoma microenvironment conversion towards immunogenicity |
| isil_str_mv | LFER |
| issn | 1999-4915 |
| kxp_id_str | 1576368491 |
| language | English |
| last_indexed | 2023-02-16T01:37:19.835Z |
| local_heading_facet_dezwi2 | immune suppression, immunogenic conversion, oncolytic H-1 parvovirus, oncolytic immunotherapy, oncolytic virotherapy, recurrent glioblastoma, tumor microenvironment |
| marc024a_ct_mv | 10.3390/v9120382 |
| match_str | angelova2017immunotherapeuticpotentialofoncolytich1parvovirushintsofglioblastomamicroenvironmentconversiontowardsimmunogenicity |
| mega_collection | Verbunddaten SWB, Lizenzfreie Online-Ressourcen |
| misc_de105 | EBOOK |
| multipart_link | 311326080 |
| multipart_part | (311326080)9(2017,12), Artikel-Nummer 382, 12 Seiten |
| names_id_str_mv | (DE-588)1079566295, (DE-627)841239908, (DE-576)452802687, (DE-588)123632862, (DE-627)706375475, (DE-576)293799326, (DE-588)1032681187, (DE-627)738641200, (DE-576)168441233 |
| oclc_num | 1341011718 |
| physical | 12 |
| publishDate | 15 December 2017 |
| publishDateSort | 2017 |
| publishPlace | |
| publisher | |
| record_format | marcfinc |
| record_id | 506368491 |
| recordtype | marcfinc |
| rvk_facet | No subject assigned |
| source_id | 0 |
| spelling | Angelova, Assia L. VerfasserIn (DE-588)1079566295 (DE-627)841239908 (DE-576)452802687 aut, Immunotherapeutic potential of oncolytic H-1 parvovirus hints of glioblastoma microenvironment conversion towards immunogenicity Assia L. Angelova, Milena Barf, Karsten Geletneky, Andreas Unterberg and Jean Rommelaere, 15 December 2017, 12, Text txt rdacontent, Computermedien c rdamedia, Online-Ressource cr rdacarrier, Gesehen am 14.06.2018, Glioblastoma, one of the most aggressive primary brain tumors, is characterized by highly immunosuppressive microenvironment. This contributes to glioblastoma resistance to standard treatment modalities and allows tumor growth and recurrence. Several immune-targeted approaches have been recently developed and are currently under preclinical and clinical investigation. Oncolytic viruses, including the autonomous protoparvovirus H-1 (H-1PV), show great promise as novel immunotherapeutic tools. In a first phase I/IIa clinical trial (ParvOryx01), H-1PV was safe and well tolerated when locally or systemically administered to recurrent glioblastoma patients. The virus was able to cross the blood-brain (tumor) barrier after intravenous infusion. Importantly, H-1PV treatment of glioblastoma patients was associated with immunogenic changes in the tumor microenvironment. Tumor infiltration with activated cytotoxic T cells, induction of cathepsin B and inducible nitric oxide (NO) synthase (iNOS) expression in tumor-associated microglia/macrophages (TAM), and accumulation of activated TAM in cluster of differentiation (CD) 40 ligand (CD40L)-positive glioblastoma regions was detected. These are the first-in-human observations of H-1PV capacity to switch the immunosuppressed tumor microenvironment towards immunogenicity. Based on this pilot study, we present a tentative model of H-1PV-mediated modulation of glioblastoma microenvironment and propose a combinatorial therapeutic approach taking advantage of H-1PV-induced microglia/macrophage activation for further (pre)clinical testing., immune suppression, immunogenic conversion, oncolytic H-1 parvovirus, oncolytic immunotherapy, oncolytic virotherapy, recurrent glioblastoma, tumor microenvironment, Geletneky, Karsten 1964- VerfasserIn (DE-588)123632862 (DE-627)706375475 (DE-576)293799326 aut, Unterberg, Andreas VerfasserIn (DE-588)1032681187 (DE-627)738641200 (DE-576)168441233 aut, Enthalten in Viruses Basel : MDPI, 2009 9(2017,12), Artikel-Nummer 382, 12 Seiten Online-Ressource (DE-627)609775871 (DE-600)2516098-9 (DE-576)311326080 1999-4915 nnns, volume:9 year:2017 number:12 extent:12, http://dx.doi.org/10.3390/v9120382 Verlag Resolving-System kostenfrei Volltext, http://dx.doi.org/10.3390/v9120382 LFER, LFER 2018-07-10T00:00:00Z |
| spellingShingle | Angelova, Assia L., Geletneky, Karsten, Unterberg, Andreas, Immunotherapeutic potential of oncolytic H-1 parvovirus: hints of glioblastoma microenvironment conversion towards immunogenicity, Glioblastoma, one of the most aggressive primary brain tumors, is characterized by highly immunosuppressive microenvironment. This contributes to glioblastoma resistance to standard treatment modalities and allows tumor growth and recurrence. Several immune-targeted approaches have been recently developed and are currently under preclinical and clinical investigation. Oncolytic viruses, including the autonomous protoparvovirus H-1 (H-1PV), show great promise as novel immunotherapeutic tools. In a first phase I/IIa clinical trial (ParvOryx01), H-1PV was safe and well tolerated when locally or systemically administered to recurrent glioblastoma patients. The virus was able to cross the blood-brain (tumor) barrier after intravenous infusion. Importantly, H-1PV treatment of glioblastoma patients was associated with immunogenic changes in the tumor microenvironment. Tumor infiltration with activated cytotoxic T cells, induction of cathepsin B and inducible nitric oxide (NO) synthase (iNOS) expression in tumor-associated microglia/macrophages (TAM), and accumulation of activated TAM in cluster of differentiation (CD) 40 ligand (CD40L)-positive glioblastoma regions was detected. These are the first-in-human observations of H-1PV capacity to switch the immunosuppressed tumor microenvironment towards immunogenicity. Based on this pilot study, we present a tentative model of H-1PV-mediated modulation of glioblastoma microenvironment and propose a combinatorial therapeutic approach taking advantage of H-1PV-induced microglia/macrophage activation for further (pre)clinical testing., immune suppression, immunogenic conversion, oncolytic H-1 parvovirus, oncolytic immunotherapy, oncolytic virotherapy, recurrent glioblastoma, tumor microenvironment |
| swb_id_str | 506368491 |
| title | Immunotherapeutic potential of oncolytic H-1 parvovirus: hints of glioblastoma microenvironment conversion towards immunogenicity |
| title_auth | Immunotherapeutic potential of oncolytic H-1 parvovirus hints of glioblastoma microenvironment conversion towards immunogenicity |
| title_full | Immunotherapeutic potential of oncolytic H-1 parvovirus hints of glioblastoma microenvironment conversion towards immunogenicity Assia L. Angelova, Milena Barf, Karsten Geletneky, Andreas Unterberg and Jean Rommelaere |
| title_fullStr | Immunotherapeutic potential of oncolytic H-1 parvovirus hints of glioblastoma microenvironment conversion towards immunogenicity Assia L. Angelova, Milena Barf, Karsten Geletneky, Andreas Unterberg and Jean Rommelaere |
| title_full_unstemmed | Immunotherapeutic potential of oncolytic H-1 parvovirus hints of glioblastoma microenvironment conversion towards immunogenicity Assia L. Angelova, Milena Barf, Karsten Geletneky, Andreas Unterberg and Jean Rommelaere |
| title_in_hierarchy | Immunotherapeutic potential of oncolytic H-1 parvovirus: hints of glioblastoma microenvironment conversion towards immunogenicity / Assia L. Angelova, Milena Barf, Karsten Geletneky, Andreas Unterberg and Jean Rommelaere, |
| title_short | Immunotherapeutic potential of oncolytic H-1 parvovirus |
| title_sort | immunotherapeutic potential of oncolytic h 1 parvovirus hints of glioblastoma microenvironment conversion towards immunogenicity |
| title_sub | hints of glioblastoma microenvironment conversion towards immunogenicity |
| topic | immune suppression, immunogenic conversion, oncolytic H-1 parvovirus, oncolytic immunotherapy, oncolytic virotherapy, recurrent glioblastoma, tumor microenvironment |
| topic_facet | immune suppression, immunogenic conversion, oncolytic H-1 parvovirus, oncolytic immunotherapy, oncolytic virotherapy, recurrent glioblastoma, tumor microenvironment |
| url | http://dx.doi.org/10.3390/v9120382 |